Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study — Toni Maria Klein (2021) | RDL Network
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
Article 2021 en
Authors
TK
Toni Maria Klein
CB
Christine Blome
CK
C. Elise Kleyn
Abstract
1 min read
Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes.
Matthias Augustin, C. Elise Kleyn, Curdin Conrad, Paul Sator, Mona Ståhle, Kilian Eyerich, M.A. Radtke, Christine Bundy, L. Mellars, Chiara Greggio, Myriam Cordey, V. Koscielny, Christopher Em Griffiths
H. Bachelez, Christopher Em Griffiths, Kim Papp, Stephen Hall, Joseph F. Merola, Steven R. Feldman, Majed Khraishi, Huaming Tan, Lara Fallon, Joseph C. Cappelleri, Andrew G. Bushmakin, Pamela Young
Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths
Ronald C. Kessler, Alan E. Kazdin, Sergio Aguilar‐Gaxiola, Jordi Alonso, Yasmin Altwaijri, Laura Helena Andrade, Corina Benjet, Chrianna Bharat, Guilherme Borges, Ronny Bruffaerts, Brendan Bunting, José Miguel Caldas‐de‐Almeida, Graça Cardoso, Wai Tat Chiu, Alfredo H. Cía, Marius Ciutan, Louisa Degenhardt, Giovanni de Girolamo, Peter de Jonge, Ymkje Anna de Vries, Silvia Florescu, Oye Gureje,
Discussion(0)
No comments yet. Be the first to comment.